Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tadalafil

FDA-approved product (tablet, oral), marketed as Adcirca, Alyq, Chewtadzy and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tadalafil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Erectile dysfunction
  • Impotence
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
FDA pharmacologic class
Phosphodiesterase 5 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tadalafil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tadalafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

    NCT07722884 · start 2026-07-01

    Registered record
    Registry ID
    NCT07722884
    Conditions
    Safety; Efficacy; Tamsulosin; Monotherapy; Tadalafil; Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
    Interventions
    Tamsulosin 0.4 mg + Tadalafil 2.5 mg; Tamsulosin 0.4 mg + Tadalafil 5 mg; Tamsulosin 0.4 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2027-01-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety; Efficacy; Tamsulosin; Monotherapy +3 more
    InterventionTamsulosin 0.4 mg + Tadalafil 2.5 mg; Tamsulosin 0.4 mg + Tadalafil 5 mg; Tamsulosin 0.4 mg
    PhaseNot applicable
    Registry statusRecruiting

  • Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

    NCT07416968 · start 2025-09-01

    Registered record
    Registry ID
    NCT07416968
    Conditions
    Overactive Bladder (OAB); Overactive Bladder Syndrome
    Interventions
    Tadalafil 5 mg; Solifenacin 5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-09-01
    Completion
    2026-12
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder (OAB); Overactive Bladder Syndrome
    InterventionTadalafil 5 mg; Solifenacin 5mg
    PhasePhase 4
    Registry statusRecruiting

  • PDE5 Inhibitor for Alzheimer's Disease

    NCT07172815 · start 2025-09

    Registered record
    Registry ID
    NCT07172815
    Conditions
    Alzheimer Disease
    Interventions
    tadalafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-09
    Completion
    2028-08
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventiontadalafil; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Evaluation of Tadalafil Combined With LIPUS for Treating Erectile Dysfunction

    NCT06543628 · start 2024-08-11

    Registered record
    Registry ID
    NCT06543628
    Conditions
    Erectile Dysfunction
    Interventions
    Tadalafil 5mg; LIPUS (Low Intensity Pulsed Ultrasound)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-08-11
    Completion
    2025-03-03
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionTadalafil 5mg; LIPUS (Low Intensity Pulsed Ultrasound)
    PhaseNot applicable
    Registry statusCompleted

  • Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes

    NCT06520839 · start 2024-05-17

    Registered record
    Registry ID
    NCT06520839
    Conditions
    Erectile Dysfunction With Diabetes Mellitus
    Interventions
    Tadalafil 5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-05-17
    Completion
    2024-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction With Diabetes Mellitus
    InterventionTadalafil 5mg
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate

    NCT05955001 · start 2023-04-01

    Registered record
    Registry ID
    NCT05955001
    Conditions
    Erectile Dysfunction; Lower Urinary Tract Symptoms
    Interventions
    Tadalafil 5mg / Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-04-01
    Completion
    2025-07
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Lower Urinary Tract Symptoms
    InterventionTadalafil 5mg / Placebo
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

    NCT05179876 · start 2022-05-04

    Registered record
    Registry ID
    NCT05179876
    Conditions
    Hypertension, Pulmonary
    Interventions
    Macitentan; Selexipag; Macitentan/Tadalafil FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-05-04
    Completion
    2030-09-30
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionMacitentan; Selexipag; Macitentan/Tadalafil FDC
    PhasePhase 3
    Registry statusRecruiting

  • (Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

    NCT05236634 · start 2022-05-01

    Registered record
    Registry ID
    NCT05236634
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Phosphodiesterase 5 Inhibitors; Alpha Blockers; Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-05-01
    Completion
    2024-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionPhosphodiesterase 5 Inhibitors; Alpha Blockers; Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Tolerability of Tadalafil Versus Darifenacin in Management of Ureteric Stent-Related LUTS

    NCT07206706 · start 2022-05-01

    Registered record
    Registry ID
    NCT07206706
    Conditions
    Management of Ureteric Stent Related LUTS and Pain
    Interventions
    Tadalafil 5Mg Tab; Darifenacin 7.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-05-01
    Completion
    2022-12-28
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionManagement of Ureteric Stent Related LUTS and Pain
    InterventionTadalafil 5Mg Tab; Darifenacin 7.5 MG
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficiency of Tadalafil for Management of Female Sexual Dysfunction

    NCT05266651 · start 2022-03-10

    Registered record
    Registry ID
    NCT05266651
    Conditions
    Sexual Dysfunction
    Interventions
    Tadalafil 5mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2022-03-10
    Completion
    2022-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Dysfunction
    InterventionTadalafil 5mg; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

    NCT05030623 · start 2021-08-01

    Registered record
    Registry ID
    NCT05030623
    Conditions
    Major Depressive Disorder
    Interventions
    Tadalafil 5Mg Tab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2021-08-01
    Completion
    2024-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionTadalafil 5Mg Tab; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Low Intensity Shock-wave Therapy (Li-ESWT) in Penile Rehabilitation After Radical Prostatectomy

    NCT03862599 · start 2021-06-01

    Registered record
    Registry ID
    NCT03862599
    Conditions
    Erectile Dysfunction Following Radical Prostatectomy
    Interventions
    Extra-corporeal shockwave therapy (ESWT); Standard care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2025-05-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction Following Radical Prostatectomy
    InterventionExtra-corporeal shockwave therapy (ESWT); Standard care
    PhaseNot applicable
    Registry statusUnknown

  • Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study

    NCT05818670 · start 2020-11-11

    Registered record
    Registry ID
    NCT05818670
    Conditions
    BPH
    Interventions
    Tamsulosin; Tadalafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-11-11
    Completion
    2022-09-17
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH
    InterventionTamsulosin; Tadalafil
    PhasePhase 4
    Registry statusCompleted

  • A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

    NCT04235270 · start 2020-01-17

    Registered record
    Registry ID
    NCT04235270
    Conditions
    Healthy
    Interventions
    FDC of Macitentan and Tadalafil; Macitentan; Tadalafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-17
    Completion
    2020-07-17
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFDC of Macitentan and Tadalafil; Macitentan; Tadalafil
    PhasePhase 1
    Registry statusCompleted

  • o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

    NCT07333976 · start 2020-01-05

    Registered record
    Registry ID
    NCT07333976
    Conditions
    Prostate Cancer Metastatic Disease; Chemotherapy Induced Peripheral Neuropathy (CIPN); Neurotoxicity
    Interventions
    Tadalafil 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-05
    Completion
    2024-08-13
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Disease; Chemotherapy Induced Peripheral Neuropathy (CIPN); Neurotoxicity
    InterventionTadalafil 5 mg
    PhasePhase 2
    Registry statusCompleted